Devin Dersh
Overview
Explore the profile of Devin Dersh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seedhom M, Dersh D, Yewdell J
Bio Protoc
. 2025 Jan;
15(2):e5165.
PMID: 39872714
Protein synthesis is by far the most energetically costly cellular process in rapidly dividing cells. Quantifying translating ribosomes in individual cells and their average mRNA transit rate is arduous. Quantitating...
2.
Du H, Mallik L, Hwang D, Sun Y, Kaku C, Hoces D, et al.
Nat Biotechnol
. 2024 Dec;
PMID: 39672954
Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck in the development of targeted...
3.
Seedhom M, Dersh D, Holly J, Pavon-Eternod M, Wei J, Angel M, et al.
Elife
. 2024 Mar;
12.
PMID: 38512721
Rapid lymphocyte cell division places enormous demands on the protein synthesis machinery. Flow cytometric measurement of puromycylated ribosome-associated nascent chains after treating cells or mice with translation initiation inhibitors reveals...
4.
5.
Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules
Papadaki G, Ani O, Florio T, Young M, Danon J, Sun Y, et al.
Front Immunol
. 2023 Feb;
14:1116906.
PMID: 36761745
Major Histocompatibility Complex class I (MHC-I) molecules display self, viral or aberrant epitopic peptides to T cell receptors (TCRs), which employ interactions between complementarity-determining regions with both peptide and MHC-I...
6.
Huang S, Zhang W, Katanski C, Dersh D, Dai Q, Lolans K, et al.
Genome Biol
. 2021 Dec;
22(1):330.
PMID: 34872593
Pseudouridine (Ψ) is an abundant mRNA modification in mammalian transcriptome, but its functions have remained elusive due to the difficulty of transcriptome-wide mapping. We develop a nanopore native RNA sequencing...
7.
Dersh D, Yewdell J
J Clin Invest
. 2021 Jan;
131(1).
PMID: 33393509
The success of tumor immunotherapy, while partial, confirms the existence and importance of tumor immunosurveillance. CD8+ T cell recognition of tumor-specific peptides bound to MHC class I (MHC-I) molecules is...
8.
Dersh D, Phelan J, Gumina M, Wang B, Arbuckle J, Holly J, et al.
Immunity
. 2020 Dec;
54(1):116-131.e10.
PMID: 33271120
Tumors frequently subvert major histocompatibility complex class I (MHC-I) peptide presentation to evade CD8 T cell immunosurveillance, though how this is accomplished is not always well defined. To identify the...
9.
Dersh D, Holly J, Yewdell J
Nat Rev Immunol
. 2020 Sep;
20(10):644.
PMID: 32873889
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Dersh D, Holly J, Yewdell J
Nat Rev Immunol
. 2020 Aug;
21(2):116-128.
PMID: 32820267
The remarkable success of immune checkpoint inhibitors demonstrates the potential of tumour-specific CD8 T cells to prevent and treat cancer. Although the number of lives saved by immunotherapy mounts, only...